Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. (SPRY) Stock Overview

Explore ARS Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

SPRY●NASDAQ
HealthcareBiotechnology
$5.31
$0.20(3.54%)
U.S. Market is Open · 15:17

ARS Pharmaceuticals, Inc. (SPRY)

Meyka AI Score

Z

Key Financials

Market Cap546.7M
P/E Ratio-2.53
EPS (TTM)$-2.18
ROE-2.57%
Fundamental Analysis

AI Price Forecasts

1 Month$0.22
3 Months$0.00
1 Year Target$5.69

SPRY Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, ARS Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of SPRY on the NASDAQ shows an RSI of 39.12, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $5.69 for the NASDAQ listing.

Key metrics behind ARS Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of -2.53 and a market capitalization of 546.7M. Combined with our AI analysis, these give both institutional and retail investors a clear view of SPRY on the NASDAQ.

Price Performance (NASDAQ: SPRY)

1-Day Change
N/A
5-Day Change
7.94%
1-Month Change
-13.44%
3-Month Change
-33.11%
6-Month Change
-38.83%
Year-to-Date (YTD) Change
-52.75%
1-Year Change
-62.98%
3-Year Change
-21.47%
5-Year Change
-80.07%
All-Time (Max) Change
-77.98%

Contact Information

https://ars-pharma.com
858 335 1300
11682 El Camino Real, San Diego, CA, 92130

Company Facts

1,630 Employees
IPO DateDec 4, 2020
CountryUS
Actively Trading

Frequently Asked Questions